These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7381687)

  • 1. [The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)].
    Taira K; Yasuda Y; Shindo T; Mitani N; Akazawa A
    Yakugaku Zasshi; 1980 Mar; 100(3):272-9. PubMed ID: 7381687
    [No Abstract]   [Full Text] [Related]  

  • 2. [The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione(suxibuzone), antiinflammatory drug. I. Plasma levels and urinary excretion after oral administration of suxibuzone (author's transl)].
    Shindo T; Yasuda Y; Taira K; Mitani N; Kanda A; Akazawa A
    Yakugaku Zasshi; 1979 Dec; 99(12):1186-200. PubMed ID: 120893
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans.
    Yasuda Y; Shindo T; Mitani N; Ishida N; Oono F; Kageyama T
    J Pharm Sci; 1982 May; 71(5):565-72. PubMed ID: 7097505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption and distribution of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA2370) in the rat.
    Coppi G; Vidi A; Gallazzi A; Perego R
    Arzneimittelforschung; 1974 May; 24(5):801-2. PubMed ID: 4408147
    [No Abstract]   [Full Text] [Related]  

  • 5. The disposition of suxibuzone in the horse.
    Delbeke FT; Vynckier L; Debackere M
    J Vet Pharmacol Ther; 1993 Sep; 16(3):283-90. PubMed ID: 8230399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 1. Serum levels and urinary excretion in rats, rabbits and dogs.
    Coppi G; Bonardi G; Perego R
    Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:234-6. PubMed ID: 5067199
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical efficiency of the anti-inflammatory anesthetic combination suxibuzone-N.A.P.A].
    Sariols Gómez M
    Rev Esp Reum Enferm Osteoartic; 1976; 19(3):305-12. PubMed ID: 792973
    [No Abstract]   [Full Text] [Related]  

  • 8. [The use of analgesic and antiphlogistic agents in small animals (author's transl)].
    Meutstege FJ
    Tijdschr Diergeneeskd; 1975 May; 100(9):509-15. PubMed ID: 241131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 2. Ulcerogenic effects in rats and dogs.
    Marazzi-Uberti E; Bianchi C; Gaetani M; Pozzi L
    Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:191-6. PubMed ID: 5067472
    [No Abstract]   [Full Text] [Related]  

  • 10. A double-blind comparison of phenylbutazone and suxibuzone, a prodrug of phenylbutazone, in rheumatoid arthritis.
    Mizushima Y; Shiokawa Y; Honma M; Kageyama T
    Int J Tissue React; 1983; 5(1):35-9. PubMed ID: 6345427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the palatability of three nonsteroidal antiinflammatory top-dress formulations in horses.
    Longhofer SL; Reinemeyer CR; Radecki SV
    Vet Ther; 2008; 9(2):122-7. PubMed ID: 18597250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 1. Anti-inflammatory, analgesic and antipyretic properties.
    Bianchi C; Lumachi B; Marazzi-Uberti E
    Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:183+. PubMed ID: 5067190
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacokinetics and tolerance of an orally administered combination preparation containing phenylbutazone and prednisolone in the dog].
    Kietzmann M; Meyer-Lindenberg A; Engelke A; Nolte I
    Dtsch Tierarztl Wochenschr; 1996 Jan; 103(1):14-6. PubMed ID: 8647008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of top-dress formulations of suxibuzone and phenylbutazone on development of gastric ulcers in horses.
    Andrews FM; Reinemeyer CR; Longhofer SL
    Vet Ther; 2009; 10(3):113-20. PubMed ID: 20037965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The distribution and excretion of 14C- and 3H-labelled 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in the rat.
    Dean HG; Donovan B; Rylett P
    Arzneimittelforschung; 1976; 26(8):1574-81. PubMed ID: 1036955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and evaluation of electrophilic derivatives of phenylbutazone as inhibitors of prostaglandin-H synthase.
    Vennerstrom JL; Holmes TJ
    J Med Chem; 1987 Mar; 30(3):563-7. PubMed ID: 3102742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous high-performance liquid chromatographic determination of suxibuzone and its metabolites in plasma and urine.
    Marunaka T; Shibata T; Minami Y; Umeno Y; Shindo T
    J Pharm Sci; 1980 Nov; 69(11):1258-61. PubMed ID: 7452452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of topical administration of antiinflammatory drugs to rats with adjuvant arthritis.
    Heilman RD; Reo RR
    Arthritis Rheum; 1975; 18(5):519-23. PubMed ID: 1191354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experimentation of the local application with a new venotropic drug (phlebolan spray) (author's transl)].
    Berson I
    Schweiz Rundsch Med Prax; 1974 Apr; 63(13):396-8. PubMed ID: 4826743
    [No Abstract]   [Full Text] [Related]  

  • 20. The biotransformation of phenylbutazone (Butazolidin).
    Faigle JW; Dieterle W
    J Int Med Res; 1977; 5 Suppl 2():2-14. PubMed ID: 410685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.